Marques Marli, Cunha Eunice Atsuko Totumi, Evangelista Maria do Socorro Nantua, Basta Paulo Cesar, Marques Ana Maria Campos, Croda Julio, de Andrade Sonia Maria Oliveira
Universidade Federal de Mato Grosso do Sul, Programa de Pós-Graduação em Doenças Infecciosas e Parasitárias, Campo Grande (MS), Brasil.
Laboratório Central de Saúde Pública de Mato Grosso do Sul, Campo Grande (MS), Brasil.
Rev Panam Salud Publica. 2017 Apr 20;41:e9. doi: 10.26633/RPSP.2017.9.
To estimate the rate of drug resistance among pulmonary tuberculosis (PTB) cases in the state of Mato Grosso do Sul, Brazil, and specifically in the border areas with Paraguay and Bolivia, as well as to identify associated risk factors.
The present cross-sectional, epidemiological study focused on PTB cases recorded between January 2007 and December 2010 in the State Reportable Disease Information System with results of susceptibility tests to rifampicin, isoniazid, ethambutol, and streptomycin. Dependent variables were development of resistance to a single drug or any combination of drugs. Independent variables were being a new or treated case, living in border areas, presence/absence of diabetes, and history of alcoholism.
There were 789 TBP cases with susceptibility testing. The following characteristics were associated with resistance: treated case (P = 0.0001), border region (P = 0.0142), alcoholism (P = 0.0451), and diabetes (P = 0.0708). The rates of combined, primary, and acquired resistance for the state were 16.3%, 10.6%, and 39.0%, vs. 22.3%, 19.2%, and 37.5% for the border region. The rates of combined, primary, and acquired multidrug resistance for the state were 1.8%, 0.6%, and 6.3%, vs. 3.1%, 1.2%, and 12.5% for the border region.
In the border region, the state should investigate drug resistance in all patients with respiratory symptoms, determine the pattern of resistance in confirmed cases, adopt directly observed treatment for cases of PTB, and develop health actions together with neighboring countries. Across the state, the levels of acquired resistance should be monitored, with investigation of resistance in all treated cases and implementation of directly observed treatment especially among patients with diabetes or alcoholism.
评估巴西南马托格罗索州肺结核(PTB)病例的耐药率,特别是与巴拉圭和玻利维亚接壤地区的耐药率,并确定相关风险因素。
本横断面流行病学研究聚焦于2007年1月至2010年12月在国家法定疾病信息系统中记录的PTB病例,这些病例有对利福平、异烟肼、乙胺丁醇和链霉素的药敏试验结果。因变量为对单一药物或任何药物组合产生耐药性。自变量为新发病例或已治疗病例、居住在边境地区、是否患有糖尿病以及酗酒史。
有789例PTB病例进行了药敏试验。以下特征与耐药性相关:已治疗病例(P = 0.0001)、边境地区(P = 0.0142)、酗酒(P = 0.0451)和糖尿病(P = 0.0708)。该州的联合耐药、原发耐药和获得性耐药率分别为16.3%、10.6%和39.0%,而边境地区分别为22.3%、19.2%和37.5%。该州的联合多药耐药、原发多药耐药和获得性多药耐药率分别为1.8%、0.6%和6.3%,而边境地区分别为3.1%、1.2%和12.5%。
在边境地区,该州应调查所有有呼吸道症状患者的耐药情况,确定确诊病例的耐药模式,对PTB病例采用直接观察治疗,并与邻国共同开展卫生行动。在全州范围内,应监测获得性耐药水平,调查所有已治疗病例的耐药情况,并实施直接观察治疗,特别是在糖尿病或酗酒患者中。